Sign Of The Times: Late-Stage Cancer Vaccines On Display At ASCO
This article was originally published in The Pink Sheet Daily
Vindicated by the approvals of Provenge and Yervoy, a host of therapeutic cancer vaccines is working through late-stage trials with the regulatory finish line in sight, and some of those companies will be presenting data at the American Society of Clinical Oncology meeting in Chicago June 1-5.
You may also be interested in...
Generex Likes Chances For Partnering AE37 Breast Cancer Vaccine
The vaccine trains specialized immune cells to act against a HER2 peptide. Created using Antigen Express’ Ii-Key Hybrid platform, Generex says AE37 has none of the restrictions that will limit the market potential of other HER2 peptide vaccines in development.
In Europe, A Public-Private Effort Could Shed Light On The Tricky Business Of Cancer Vaccines
With EU cash in hand, the GAPVAC consortium aims to develop tailor-made vaccines for patients with the rare but aggressive brain cancer, glioblastoma. The vaccines will be unique to each individual, but hopefully with increased efficacy compared with other therapies, thereby justifying the likely higher cost and complexity of treatment.
New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines
A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.